Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials

Collaborators, Affiliations

¹ Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.
² University of Exeter Medical School, London, UK. gennaro.pagano@roche.com.
³ Roche Products Ltd, Welwyn Garden City, UK.
⁴ Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁵ Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.
⁶ Institute for Neurodegenerative Disorders, New Haven, CT, USA.
⁷ Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.
¹⁰ Roche Diagnostics GmbH, Penzberg, Germany.

Published Erratum

Gennaro Pagano et al. NPJ Parkinsons Dis. 2025.

. 2025 Aug 13;11(1):241.

doi: 10.1038/s41531-025-01103-y.

¹ Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.
² University of Exeter Medical School, London, UK. gennaro.pagano@roche.com.
³ Roche Products Ltd, Welwyn Garden City, UK.
⁴ Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁵ Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.
⁶ Institute for Neurodegenerative Disorders, New Haven, CT, USA.
⁷ Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.
¹⁰ Roche Diagnostics GmbH, Penzberg, Germany.

No abstract available

Erratum for

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.